Barker, Fingert, Hayes-Jordan and Vadaparampil named to NCAB

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Anna D. Barker
Howard Fingert
Howard Fingert
Andrea Hayes-Jordan
Susan T. Vadaparampil

The White House has named the following individuals to the National Cancer Advisory Board:

  • Anna D. Barker, director of Arizona State University Transformative Healthcare Networks, co-director of the Complex Adaptive Systems Initiative and as a professor of practice within the School of Life Sciences. She is also a former NCI deputy director.

  • Howard Fingert, a long-time biotechnology company executive who now works as an industry consultant. Fingert is a member of the NCI Clinical Trials and Translational Research Advisory Committee and a former industry representative on the FDA Oncologic Drugs Advisory Committee.

  • Andrea Hayes-Jordan, chief of the Division of Pediatric Surgery at the UNC School of Medicine, and surgeon-in-chief at the North Carolina Children’s Hospital.

  • Susan T. Vadaparampil, associate center director of Community Outreach, Engagement, & Equity at Moffitt Cancer Center. She joined the Moffitt faculty after completing postdoctoral training at the NCI. Her work is focused on health disparities.

Table of Contents

YOU MAY BE INTERESTED IN

The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly for weight management, represents one of the most significant shifts in metabolic medicine in decades. With millions of people now using medications such as semaglutide and tirzepatide, we are witnessing a fundamental alteration in patient physiology that extends far beyond glucose control and weight loss. As these drugs approach 10% population penetrance in some demographics, the oncology community faces an urgent question: How will this metabolic transformation reshape cancer care?

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login